Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Optical Coherence Tomography of Retinal Abnormalities Associated With Choroidal Nevus, Choroidal Melanoma and Choroidal Melanoma Treated With Iodine-125 Brachytherapy

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2016 by Jonsson Comprehensive Cancer Center
Sponsor:
Information provided by (Responsible Party):
Jonsson Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT00346372
First received: June 27, 2006
Last updated: July 5, 2016
Last verified: July 2016

June 27, 2006
July 5, 2016
March 2004
September 2017   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00346372 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Optical Coherence Tomography of Retinal Abnormalities Associated With Choroidal Nevus, Choroidal Melanoma and Choroidal Melanoma Treated With Iodine-125 Brachytherapy
Not Provided
During regularly scheduled appointments, Optical Coherence Tomography (OCT) is performed on consented subjects. The OCT is a new type of camera that takes very detailed pictures inside of the eye and deeper into eye tissues. Optical Coherence Tomography imaging of intraocular tumors may lead to improved diagnosis and monitoring of tumors within the eye.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Patients who meet the following Eligibility Criteria
Ocular Melanoma
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
800
Not Provided
September 2017   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adults (18 years or older) with:

    • choroidal nevus greater than or equal to 3.0 mm in longest basal diameter, or greater than or equal to 1.25 mm in apical height or:
    • choroidal melanoma located in the posterior pole (4mm or less from the center of fovea or the border of the optic nerve head)

Exclusion Criteria:

  • Ocular media opacity in the tumor eye that prevents adequate functional testing or imaging and prior or concurrent retinal or choroidal disease in the tumor eye that prevents adequate functional testing or imaging
Both
18 Years and older   (Adult, Senior)
No
Contact: Tara A McCannel, MD, PhD (310) 206-7484 tmccannel@jsei.ucla.edu
Contact: Brangel Rangel 310 794-9962 Brangel@jsei.ucla.edu
United States
 
NCT00346372
UCLA IRB#03-11-052
Not Provided
Not Provided
Not Provided
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Not Provided
Principal Investigator: Bradley R Straatsma, MD, JD Jules Stein Eye Institute, UCLA
Jonsson Comprehensive Cancer Center
July 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP